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Background: Cinaciguat (BAY 58-2667) is a soluble guanylate cyclase (sGC) activator that is being developed as a first-in-class treatment 
for acute decompensated heart failure (ADHF). It acts independently of the sGC ligand nitric oxide, and its potency is increased in conditions of 
oxidative stress. Cinaciguat showed cardioprotective effects in animal models, and pilot clinical studies found that it was well tolerated, unloaded 
the heart and increased cardiac output.
Methods: This placebo-controlled, randomized, double-blind, multicenter, international phase IIb study investigated the safety and efficacy 
of intravenous cinaciguat (per-protocol) as add-on to standard therapy in 139 patients with ADHF monitored via Swan-Ganz thermodilution 
catheterization (NYHA functional class III and IV; pulmonary capillary wedge pressure [PCWP] ≥ 18 mmHg). In the per-protocol analysis group 
(with 2:1 randomization), 90 patients received cinaciguat and 49 received placebo. The cinaciguat dose was titrated (according to systolic blood 
pressure) from 100 μg/h to a maximum of 600 μg/h for the first 8 h, and was then maintained for up to 40 h. The primary endpoint was a change in 
PCWP after 8 h compared with placebo. Secondary endpoints included hemodynamic and safety parameters, organ protection and 30-day mortality.
Results: Patients on stable standard therapy were enrolled into the study within 48 h after hospital admission. Cinaciguat caused a rapid and 
sustained decrease in the primary endpoint PCWP compared with placebo (p < 0.0001), increased cardiac output (p < 0.001) and reduced 
pulmonary vascular resistance (PVR) without causing a clinically significant change in heart rate. No adverse effects on cardiac or renal function or 
30-day mortality were seen, despite an increased occurrence of asymptomatic hypotension at high doses of cinaciguat.
Conclusions: Cinaciguat rapidly and significantly reduced PCWP and PVR and increased cardiac output in patients with ADHF, without impairing 
cardiac or renal function. Hypotension occurred in some patients; further dose titration studies are therefore required to establish the optimal 
dosing strategy for this promising new therapy.
